These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31818649)

  • 21. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.
    Nicolai N; Nazzani S; Tesone A; Macchi A; Piva L; Salvioni R; Stagni S; Torelli T; Agostini E; Celso F; Giannatempo P; Procopio G; Avuzzi B; Lanocita R; Cattaneo L; Catanzaro M; Biasoni D
    Tumori; 2023 Aug; 109(4):379-386. PubMed ID: 35915559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer.
    Patel HV; Srivastava A; Kim S; Patel HD; Pierorazio PM; Bagrodia A; Masterson TA; Ghodoussipour SB; Kim IY; Singer EA; Jang TL
    J Urol; 2022 May; 207(5):1057-1066. PubMed ID: 34978466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
    Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
    Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 25. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
    Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study.
    Thor A; Myklebust MP; Grenabo Bergdahl A; Lundgren PO; Skokic V; Almås B; Haugnes HS; Tandstad T; Akre O; Cohn-Cedermark G; Dahl O; Kjellman A
    J Urol; 2024 Nov; 212(5):720-730. PubMed ID: 39052680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer: a technique to reduce morbidity].
    Aufderklamm S; Todenhöfer T; Hennenlotter J; Gakis G; Mischinger J; Mundhenk J; Germann M; Stenzl A; Schwentner C
    Urologe A; 2013 Aug; 52(8):1097-103. PubMed ID: 23416965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
    Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
    Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term results of laparoscopic retroperitoneal lymph node dissection (RPLND) in low-stage nonseminomatous germ-cell testicular tumors (NSGCTT) performed by a senior surgeon: 1999-2003].
    Pizzocaro G; Schiavo M; Solima S; Vitellaro M; Biasoni N; Nicolai N
    Urologia; 2010; 77 Suppl 17():50-6. PubMed ID: 21308676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
    Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
    Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?
    Riggs SB; Burgess EF; Gaston KE; Merwarth CA; Raghavan D
    Oncologist; 2014 May; 19(5):498-506. PubMed ID: 24718515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma.
    Rabbani F; Farivar-Mohseni H; Leon A; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2003 Dec; 62(6):1092-6. PubMed ID: 14665362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
    Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
    Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST).
    Hiester A; Che Y; Lusch A; Kuß O; Niegisch G; Lorch A; Arsov C; Albers P
    Eur Urol; 2023 Jul; 84(1):25-31. PubMed ID: 36372627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.
    Stokes W; Amini A; Maroni PD; Kessler ER; Stokes C; Cost CR; Greffe BS; Garrington TP; Liu AK; Cost NG
    J Pediatr Urol; 2017 Aug; 13(4):386.e1-386.e7. PubMed ID: 28153774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
    Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
    Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
    Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
    J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
    Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
    Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
    Heidenreich A; Thüer D; Polyakov S
    Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.